

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:518883-2018:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2018/S 227-518883**

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
Telephone: +44 1928755227
E-mail: gemma.tomlinson1@nhs.net
NUTS code: UK

Internet address(es):

Main address: <https://nhsengland.bravosolution.co.uk>

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://nhsengland.bravosolution.co.uk>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://nhsengland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the abovementioned address

Electronic communication requires the use of tools and devices that are not generally available.

Unrestricted and full direct access to these tools and devices is possible, free of charge, at: <https://nhsengland.bravosolution.co.uk>

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

National Framework Agreement for the Supply of Generic Pharmaceuticals – Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz

Reference number: CM/PHG/17/5545

II.1.2) **Main CPV code**

33600000

II.1.3) **Type of contract**

Supplies

II.1.4) **Short description:**

Invitation to offer for National Framework Agreement for the supply of generic pharmaceuticals – Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz

Offer reference number: CM/PHG/17/5545

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months potential periods of call-offs under the Framework Agreement:

- North West London: 21.5.2019 to 31.10.2020 (18 months),
- North Central and East London: 21.5.2019 to 31.10.2020 (18 months),
- South East and West London: 21.5.2019 to 31.10.2020 (18 months),
- North of England: 21.5.2019 to 31.10.2020 (18 months),
- Midlands and East: 21.5.2019 to 31.10.2020 (18 months),
- South of England: 21.5.2019 to 31.10.2020 (18 months).

II.1.5) **Estimated total value**

Value excluding VAT: 408 000 000.00 GBP

II.1.6) **Information about lots**

This contract is divided into lots: yes

Tenders may be submitted for all lots

II.2) **Description**

II.2.1) **Title:**

Lot 1: London

Lot No: 1a & 1b

II.2.2) **Additional CPV code(s)**

33600000

33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points. The Framework Agreement is intended for use by the DHSC, Public Health England and the NHS in England.

II.2.4) **Description of the procurement:**

Lot 1a: London: Tenofovir Disoproxil/Emtricitabine

Offer reference number: CM/PHG/17/5545/01

Lot 1b: London: Tenofovir Disoproxil/Emtricitabine/Efavirenz

Offer reference number: CM/PHG/17/5545/02

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months potential periods of call-offs under the Framework Agreement:

- North West London: 21.5.2019 to 31.10.2020 (18 months),
- North Central and East London: 21.5.2019 to 31.10.2020 (18 months),
- South East and West London: 21.5.2019 to 31.10.2020 (18 months).

- II.2.5) **Award criteria**
Price is not the only award criterion and all criteria are stated only in the procurement documents
- II.2.6) **Estimated value**
- II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**
Start: 21/05/2019
End: 31/10/2020
This contract is subject to renewal: no
- II.2.10) **Information about variants**
Variants will be accepted: no
- II.2.11) **Information about options**
Options: yes
Description of options:
This framework has the option to extend for up to a maximum of 18 months.
- II.2.12) **Information about electronic catalogues**
- II.2.13) **Information about European Union funds**
The procurement is related to a project and/or programme financed by European Union funds: no
- II.2.14) **Additional information**
- II.2) **Description**
- II.2.1) **Title:**
Lot 2 Rest of England
Lot No: 2a & 2b
- II.2.2) **Additional CPV code(s)**
33600000
33690000
- II.2.3) **Place of performance**
NUTS code: UK
Main site or place of performance:
Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points. The Framework Agreement is intended for use by the DHSC, Public Health England and the NHS in England.
- II.2.4) **Description of the procurement:**
Lot 2a: Rest of England: Tenofovir Disoproxil/Emtricitabine
Offer reference number: CM/PHG/17/5545/03
Lot 2b: Rest of England: Tenofovir Disoproxil/Emtricitabine/Efavirenz
Offer reference number: CM/PHG/17/5545/04
Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months potential periods of call-offs under the Framework Agreement:
— North of England: 21.5.2019 to 31.10.2020 (18 months),
— Midlands and East: 21.5.2019 to 31.10.2020 (18 months),
— South of England: 21.5.2019 to 31.10.2020 (18 months).
- II.2.5) **Award criteria**
Price is not the only award criterion and all criteria are stated only in the procurement documents
- II.2.6) **Estimated value**

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 21/05/2019

End: 31/10/2020

This contract is subject to renewal: no

II.2.10) Information about variants

Variants will be accepted: no

II.2.11) Information about options

Options: yes

Description of options:

This framework has the option to extend for up to a maximum of 18 months.

II.2.12) Information about electronic catalogues

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) Additional information

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

III.1.2) Economic and financial standing

III.1.3) Technical and professional ability

III.1.5) Information about reserved contracts

III.2) Conditions related to the contract

III.2.2) Contract performance conditions:

III.2.3) Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue

IV.1.6) Information about electronic auction

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 20/12/2018

Local time: 13:00

IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4) **Languages in which tenders or requests to participate may be submitted:**
English

IV.2.6) **Minimum time frame during which the tenderer must maintain the tender**
Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) **Conditions for opening of tenders**
Date: 20/12/2018
Local time: 13:00
Place:
Rutland House, Runcorn
Information about authorised persons and opening procedure:
Commercial Medicines Unit employee.

Section VI: Complementary information

VI.1) **Information about recurrence**
This is a recurrent procurement: no

VI.2) **Information about electronic workflows**
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used

VI.3) **Additional information:**
Responding to this notice:
Any supplier may be disqualified who does not respond to the following in the requisite manner:
1) Submission of expression of interest and procurement specific information:
This procurement exercise will be conducted on the eTendering portal at <https://nhsengland.bravosolution.co.uk>.
Candidates wishing to be considered for this procurement exercise must register, and provide additional Procurement specific information (if requested), through the eTendering portal as follows:
1.1) If not already registered, Candidates should register on the eTendering portal at <https://nhsengland.bravosolution.co.uk/web/login.html> and click the link to register:
— accept the terms and conditions and click continue,
— enter your correct business and user details,
— note the username you chose and click “Save” when complete,
— you will shortly receive an email with your unique password (please keep this secure).
1.2) Once registered, candidates must express interest as follows:
(a) login to the eTendering portal;
(b) select “Response to ITT”;
(c) select “ITTs open to all suppliers”;
(d) access listing related to this procurement, national Framework Agreement for the supply of generic pharmaceuticals – Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz, and view details;
(e) click on “Express interest” button at the top of the page;
(f) once you have expressed interest, the ITT will move to “My ITTs”, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the “Publish” button.
1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or help@bravosolution.co.uk.

2) General supplier information:

To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

- 2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page <https://supplierregistration.cabinetoffice.gov.uk> and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.
- 2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.
- 2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: support@nqc.com or telephone +44 (0) 845 299 2994.

Other Contracting Authorities:

The Framework Agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Royal Courts of Justice
London or any other district registry of the High Court
United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**
20/11/2018